Exodus Point Capital Management, LP Clovis Oncology, Inc. Transaction History

Exodus Point Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 19, 2022	SELL	$0.63 - $2.96 $97,662 - $458,859	-155,020 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.43 - $3.14 $117,477 - $257,957	82,152 Added 112.74%	155,020 $313,000
Q4 2021 Feb 11, 2022	SELL	$2.7 - $4.76 $19,801 - $34,909	-7,334 Reduced 9.14%	72,868 $197,000
Q3 2021 Nov 15, 2021	SELL	$4.06 - $5.8 $153,780 - $219,686	-37,877 Reduced 32.08%	80,202 $358,000
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $592,756 - $832,456	118,079 New	118,079 $685,000
Q4 2020 Feb 16, 2021	SELL	$4.13 - $6.41 $136,987 - $212,613	-33,169 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$4.82 - $7.72 $25,994 - $41,633	-5,393 Reduced 13.99%	33,169 $193,000
Q2 2020 Aug 14, 2020	BUY	$5.69 - $9.69 $219,417 - $373,665	38,562 New	38,562 $260,000
Q1 2020 May 15, 2020	SELL	$3.77 - $11.0 $46,804 - $136,565	-12,415 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.0 - $16.43 $37,245 - $203,978	12,415 New	12,415 $129,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.